Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

248
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
248
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

312
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
312
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

324
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
324
Hepatic Portal System01:21

Hepatic Portal System

7.3K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
7.3K
Hepatic Drug Excretion: Enterohepatic Cycling01:17

Hepatic Drug Excretion: Enterohepatic Cycling

3.2K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
3.2K
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

705
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
705

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IMAT-HCC model: Liver stiffness-enhanced integrated risk stratification for HCC recurrence after resection.

JHEP reports : innovation in hepatology·2026
Same author

HCC Is the Predominant Liver-Related Event in MASLD: 2-Step Non-Invasive Algorithms to Stratify Risk in Non-Cirrhotic Patients.

Journal of hepatocellular carcinoma·2026
Same author

The qEEG-TIPS score: Development of a predictive model for recurrent overt hepatic encephalopathy after elective TIPS.

JHEP reports : innovation in hepatology·2026
Same author

Nutritional Management of Irritable Bowel Syndrome.

Nutrients·2026
Same author

Defibrotide for prophylaxis of sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) in pediatric high-risk patients: consensus guidelines from the European Society for Blood and Marrow Transplantation (EBMT).

Bone marrow transplantation·2026
Same author

Reply: Beyond semantics-Acknowledging diagnostic differences between NAFLD and MASLD.

Hepatology (Baltimore, Md.)·2025
Same journal

Recenti progressi in medicina·2026
Same journal

Recenti progressi in medicina·2026
Same journal

Recenti progressi in medicina·2026
Same journal

Recenti progressi in medicina·2026
Same journal

Recenti progressi in medicina·2026
Same journal

Recenti progressi in medicina·2026
See all related articles

Related Experiment Video

Updated: Mar 15, 2026

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.4K

[Hepatic encephalopathy].

Davide Festi1, Giovanni Marasco1, Federico Ravaioli1

  • 1Dipartimento di Scienze Mediche e Chirurgiche, Policlinico Sant'Orsola, Università di Bologna.

Recenti Progressi in Medicina
|August 30, 2016
PubMed
Summary
This summary is machine-generated.

Hepatic encephalopathy (HE) is a liver cirrhosis complication causing neuropsychiatric issues. Treatment focuses on overt HE, using disaccharides and rifaximin, while covert HE requires individualized management.

More Related Videos

A Piglet Model of Neonatal Hypoxic-Ischemic Encephalopathy
10:30

A Piglet Model of Neonatal Hypoxic-Ischemic Encephalopathy

Published on: May 16, 2015

20.3K
Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
07:36

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats

Published on: November 20, 2015

12.0K

Related Experiment Videos

Last Updated: Mar 15, 2026

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.4K
A Piglet Model of Neonatal Hypoxic-Ischemic Encephalopathy
10:30

A Piglet Model of Neonatal Hypoxic-Ischemic Encephalopathy

Published on: May 16, 2015

20.3K
Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
07:36

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats

Published on: November 20, 2015

12.0K

Area of Science:

  • Hepatology
  • Neurology
  • Gastroenterology

Background:

  • Hepatic encephalopathy (HE) is a frequent complication of liver cirrhosis.
  • It presents with diverse neuropsychiatric symptoms impacting patient health.
  • Recent guidelines classify HE based on severity and clinical presentation.

Purpose of the Study:

  • To review the classification, pathogenic mechanisms, and therapeutic strategies for hepatic encephalopathy.
  • To highlight the distinction between covert and overt HE management.
  • To emphasize the importance of addressing precipitating factors.

Main Methods:

  • Literature review of HE classification and treatment guidelines.
  • Analysis of pathogenic mechanisms including ammonia, inflammation, and toxins.
  • Evaluation of therapeutic options for overt and covert HE.

Main Results:

  • HE is classified as unimpaired, covert (minimal/grade 1), or overt (grade 2-4).
  • Pathogenic mechanisms involve ammonia, cytokines, benzodiazepine-like compounds, and manganese.
  • Effective treatments for overt HE include lactulose, lactitol, and rifaximin.

Conclusions:

  • Overt HE management involves non-absorbable disaccharides and rifaximin.
  • Covert HE requires case-by-case management.
  • Identifying and treating precipitating factors is crucial for HE management.